Spyre Therapeutics Stock (NASDAQ:AGLE)
Previous Close
$11.26
52W Range
$2.66 - $24.00
50D Avg
$12.64
200D Avg
$9.84
Market Cap
$48.63M
Avg Vol (3M)
$59.54K
Beta
2.57
Div Yield
-
AGLE Company Profile
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
AGLE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| BLCM | Bellicum Pharmaceuticals, Inc. |
| NUVB | Nuvation Bio Inc. |
| IKNA | Ikena Oncology, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| BPTH | Bio-Path Holdings, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| LABP | Landos Biopharma, Inc. |
| HILS | Tharimmune, Inc. |
| CING | Cingulate Inc. |
| ASMB | Assembly Biosciences, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| NLTX | Neurogene Inc. |
| CBIO | Gyre Therapeutics, Inc. |
| BNTC | Benitec Biopharma Inc. |
| TIL | Instil Bio, Inc. |
| ALRN | Aileron Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |